sintilimab + chidamide + azacitidine

This combination therapy, evaluated by Peking University, consists of the PD-1 inhibitor sintilimab, the HDAC inhibitor chidamide, and the DNA methyltransferase inhibitor azacitidine. Sintilimab is a humanized monoclonal antibody that restores anti-tumor immunity by blocking the PD-1 receptor. Chidamide (also known as tucidinostat) is a benzamide-based selective HDAC inhibitor that targets HDAC1, 2, 3, and 10 to induce epigenetic reprogramming and tumor cell death. Azacitidine is a nucleoside analog that inhibits DNA methyltransferases, leading to hypomethylation of gene promoters and reactivation of tumor suppressor genes. The combination is specifically being studied for its synergistic potential in treating relapsed or refractory peripheral T-cell lymphoma (PTCL), where epigenetic dysregulation is a common driver and immune evasion is prevalent.

Other names

Sintilimab + Chidamide + AzacitidineSintilimab + Tucidinostat + AzacitidineAzacitidine + Chidamide + Sintilimab